New data suggest Vivani’s miniature exenatide implant, NPM-115, works as well as Novo Nordisk’s Wegovy and Ozempic for weight loss in mice. The implant delivers high doses of exenatide, a GLP-1 ...
NEW YORK, Oct 31 (Reuters) - Amylin Pharmaceuticals Inc said on Wednesday the once-weekly, long-acting release version of its exenatide diabetes drug proved superior at controlling glucose to the ...
AstraZeneca (NYSE: AZN) announced that the FDA has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes with ...
June 11, 2012 (Philadelphia, Pennsylvania) — In patients whose diabetes is not controlled with metformin, the addition of exenatide might be a better option than the sulfonylurea glimepiride, ...
As an investigational diabetes drug implant that promises better adherence faces FDA review for a third time, safety concerns ranging from adverse heart and kidney events are expected to be points of ...
June 9, 2009 (New Orleans, Louisiana) — A head-to-head comparison of the investigational agent liraglutide (Novo Nordisk) and exenatide (Byetta, Amylin Pharmaceuticals) shows that the former resulted ...
LOS ANGELES (Reuters) - A pump-delivered version of exenatide, the active ingredient in diabetes drug Byetta, was shown to significantly lower glucose levels in a small four-week trial, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results